Electromed Inc. (ELMD) exhibits 78.1% gross margins and 24.1% return on invested capital within Health Care (Biotechnology: Electromedical & Electrotherapeutic Apparatus), balanced against a 21.8x enterprise multiple and 4.8% implied options volatility.
Sustained 78.1% gross profitability converts into 15.1% operating margin and 24.1% ROIC, outpacing sector cost of capital.
ROIC: 24.1% // GM: 78.1%YoY revenue trajectory of +17.0% paired with 4.85% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +17.0% // FCF YLD: 4.85%Altman Z-Score of 17.64 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 17.64 // F-SCORE: 8/9Trading at 30.4x trailing P/E (25.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 30.4x // EV/EBITDA: 21.8xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $27.68 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Electromedical & Electrotherapeutic Apparatus require continuous execution to defend 11.8% net margins.
NET MARGIN: 11.8% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ELMD & activate live FRED threshold breach alerts.